Role of Gut Microbiota in Bile-Acid Metabolism by Naito, Yuji et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Role of Gut Microbiota in  
Bile-Acid Metabolism
Yuji Naito, Tomohisa Takagi and Ryo Inoue
Abstract
The role of the gut microbiota in modifying the pathophysiology of various 
diseases, including neurodegenerative diseases, is increasingly becoming clear. Bile 
acids have been shown to be endogenous factors that affect gut microbiota, and 
bile-acid metabolites directly or indirectly affect host physiology and pathophysiol-
ogy. The development of metagenomic analysis for gut microbiota and systematic 
bile-acid measurement using LC–MS/MS has triggered a breakthrough for research 
in this field. Clinically, an inhibitor of the ileal bile-acid transporter (Elobixibat) 
was used as a therapeutic agent for chronic constipation, which also paved the way 
for progress in bile-acid signal research. Additionally, this review emphasizes the 
importance of gut microbiota-bile acid-receptor signals when considering nutri-
tional approaches to promote healthy longevity.
Keywords: Akkermansia muciniphila, bile acid, gut microbiota, ileal bile-acid 
transporter, TGR5
1. Introduction
Bile acids have been studied for more than 100 years, but recently, their inter-
action with intestinal flora has been drawing attention and is being increasingly 
clarified. Bile-acid research, which has been conducted mainly in the field of liver 
disease, has led to the development of ursodeoxycholic acid (UDCA), which is 
generally accepted to improve clinical and biochemical index values in patients with 
cholestatic liver disease. TGR5 (G protein-coupled bile-acid receptor 1, GPBAR-
1), identified in 2002, is a G protein-coupled receptor with seven transmembrane 
domains and is widely distributed in various organs and tissues. TGR5 can be 
activated by primary and secondary bile acids, indicating the function of bile 
acids as signal transduction molecules and in regulating energy metabolism and 
glycolipid metabolism [1]. Bile acids undergo various metabolic processes such as 
deconjugation by intestinal bacteria; it has also been shown that the host response is 
regulated by the reaction between the metabolite and the receptor [2]. Under these 
circumstances, an inhibitor of the ileal bile-acid transporter (IBAT) localized at the 
terminal ileum has been shown to be effective in treating constipation [3, 4] and has 
become a topic of clinical research. This review focuses on the interaction between 
bile acids and gut microbiota.
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2. Classification of bile acids and their metabolites
Bile acids are synthesized from cholesterol in the liver; in humans, cholic acid 
(CA) and chenodeoxycholic acid (CDCA) are typical primary bile acids [5]. In 
the rodent liver, chenodeoxycholic acid is further converted to muricolic acid 
(MCA). After biosynthesis, CA and CDCA undergo further glycine conjugation 
or taurine conjugation in the liver. Among human conjugated bile acids, taurine 
conjugates and glycine conjugates accumulate in the gallbladder at a concentration 
ratio of approximately 1:3 and are secreted from the bile duct into the duodenum 
in response to food intake. On secretion into the duodenum, taurine conjugates 
(tauro-CA, tauro-CDCA) and glycine conjugates (glyco-CA, glyco-CDCA) are 
deconjugated by the bile salt hydrolase (BSH) of the gut microbiota; these decon-
jugated bile acids are involved in the formation of micelles and the absorption of 
dietary fat (Figure 1).
Lactobacillus plantarum, Lactobacillus johnsonii, Clostridium perfringens, and 
Bifidobacterium longum have been reported to be specific bacteria carrying the BSH 
gene [6]. Because the BSH gene is expressed in many bacteria and the presence of 
BSH is favorable to the host, the presence of these bacteria can be interpreted to 
be a result of selection by the host. BSH has been suggested to play an important 
role in the colonization and survival of bacteria in the gut [7]. Jarocki et al. [8] first 
analyzed the occurrence of BSH in 14 strains belonging to the Bifidobacterium genus 
and purified and analyzed two BSHs from B. pseudocatenulatum and B. longum 
subsp. suis for their selected biochemical and molecular features. Deconjugation by 
BSH seems to be meaningful in human physiology and is involved in the lowering 
of cholesterol levels, maintenance of intestinal homeostasis, maintenance of the 
intestinal circadian rhythm, and supply of glycine and taurine to the surround-
ing bacteria [6]. In particular, free bile acids (CA, CDCA) have been reported to 
be directly involved in the expression of clock genes in intestinal epithelial cells 
that can control peripheral circadian rhythms in the intestinal tract and liver. 
Govindarajan et al. [9] demonstrated that unconjugated bile acids are potential 
chronobiological regulators of host circadian gene expression, especially in the 
intestine and liver. These data may indicate the potential role of microbiota-gen-
erated bile acids as chronological regulators of the peripheral circadian clock and 
Figure 1. 
Synthesis, conjugation, and metabolism of bile acids by gut microbiota.
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suggest that intervention strategies that alter gut bile-acid profiles could influence 
the circadian clock. Joyce et al. [10] investigated the role bacterial BSH in the host 
physiology and have demonstrated that bacterial BSH activity significantly impacts 
the systemic metabolic processes and adiposity in the host and represents a key 
mechanistic target for the control of obesity and metabolic syndrome.
Primary bile acids are actively reabsorbed by the ileal bile-acid transporter 
(IBAT) present in the terminal ileum in addition to being passively absorbed. 
Consequently, bile acids secreted into the intestinal tract could return to the liver 
via the portal vein, 95% of which is reused. Bile acids are reported to be reused by 
enterohepatic circulation and circulated in the human body 4–12 times a day [11]. 
The details of the mechanism regulating IBAT expression have not yet been eluci-
dated; however, IBAT expression appears to be affected by gut microbiota and is 
markedly enhanced in germ-free mice [12].
Bile acids that flow from the small intestine to the large intestine are further 
metabolized by abundant gut bacteria. First, multi-step reactions of specific 
bacteria result in the hydroxyl group at the C-7a position of the deconjugated 
bile acids (CA and CDCA) being dehydroxylated (7α-dehydroxylation) to form 
secondary bile acids, such as deoxycholic acid (DCA) and lithocholic acid (LCA). 
Specifically, CA is metabolized to deoxycholic acid (DCA), which in turn is metabo-
lized to lithocholic acid (LCA). Specific Eubacterium and Clostridium cluster XIVa 
species, belonging to the Firmicutes phylum, are involved in this conversion in a 
complex manner, but the entire pathway has not yet been clarified. More than 90% 
of bile acids in feces are secondary bile acids, and in humans, DCA and LCA are 
the most abundant [13]. These bile acids affect host physiological function via the 
TGR5 receptor, which is a bile-acid receptor, and are involved in water secretion to 
the lumen of the large intestine and peristaltic movement of the tract. Therefore, 
secondary bile acids produced by the gut microbiota are essential for the physi-
ological function of the host, and a decrease in their concentration could lead to 
a corresponding decrease in intestinal peristalsis. Thus, a decrease in bile-acid 
concentrations may not only induce constipation symptoms, but also adversely 
affect the gut-brain axis.
Furthermore, some amount of CDCA is further metabolized to UDCA by gut 
bacteria carrying the 7α- and 7β-hydroxylsteroid dehydrogenase (HSDH) genes. 
Bacteria such as Ruminococcus gravus, Ruminococcus productus, Collinsella aerofaciens, 
and Clostridium absonum have the HSDH gene but have not been studied in detail. 
Although the luminal concentrations of these bile-acid metabolites in the large 
intestine are low, recent reports have reported anti-inflammatory, anti-bacterial, 
and wound healing promoting effects of these metabolites [14]; thus, further stud-
ies are required.
As described above, primary bile acids secreted into the duodenum in a conju-
gated form are metabolized by various intestinal bacterial genes. This interaction 
is complex because bile acids also have a more direct effect on the survival of the 
gut microbiota. Islam et al. [15] have demonstrated that bile acid is a host factor 
that regulates the composition of the cecal microbiota in rats, and that CA feeding 
simplifies the composition of the microbiota, with outgrowth of several bacteria 
in the classes Clostridia and Erysipelotrichi. Furthermore, importantly, several 
bile-acid receptors have been discovered and each bile acid has differing binding 
ability to these receptors; these aspects should be considered to understand the 
bile acid-mediated host response. Metabolic disorders have an impact on longev-
ity and the recent findings showed the relationship between bile acid metabolism 
and metabolic disorders [16–18]. Broeders et al. [16] have showed that CDCA 
promotes mitochondrial uncoupling via bile-acid receptor (TGR5) in human brown 
adipocytes and increases brown fat activity and energy expenditure in women. 
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Because it has been shown that TGR5 localizes in many cells and tissues, including 
enteroendocrine cells, neurons, macrophages, muscle and endothelial cells, the bile 
acid-mediated host response should be carefully analyzed.
3. Serum bile-acid profile as a biomarker
The profiles of various bile acids can be selectively measured using quantitative 
systematic liquid chromatography–tandem mass spectrometry (LC–MS/MS) for 
samples such as blood and stool. Furthermore, quantitative measurement using 
internal standard substances has made it possible to rapidly conduct research using 
a large number of clinical samples [19, 20]. Features of serum bile-acid profiles have 
been reported in patients with inflammatory bowel disease [19], colon cancer [21], 
irritable bowel syndrome [22], chronic constipation [23], liver diseases such as fatty 
liver and fatty hepatitis [24], and neurodegenerative diseases such as Alzheimer’s 
disease and cognitive dysfunction [25, 26].
The relationship between colorectal cancer and the gut microbiota is a hot topic 
of research. Fusobacterium nucreatum, detected relatively specifically in colorectal 
cancer tissues, is a sulfate-reducing bacterium that can produce hydrogen sulfide, 
which is a gene mutagen. Taurine released from taurine-conjugated bile acids has 
been suggested to be a substrate for hydrogen sulfide production [27]; therefore, 
the carcinogenic-promoting effect of a high-fat diet may be partially explained by 
the increase in levels of taurine-conjugated bile acids caused by the diet. Bile-acid 
profile information for patients with colorectal cancer has also been reported. 
Uchiyama et al. [21] measured serum bile-acid profiles of healthy individuals, 
colorectal adenomatous polyps, and colorectal cancer at each clinical stage and 
analyzed the principal components of 30 types of bile acids. Free CA, 3epi-DCA, 
CDCA, 3-dehydro CA, glyco-CA, and tauro-CA were extracted as principal compo-
nents (PC) 1 and free 3-dehydroDCA was extracted as PC 2 by canonical discrimi-
nant function coefficients. They concluded that the verification of discriminability 
using the cross-validation method revealed that the correct classification rate was 
66.3% for the original data and 52.6% for the cross-validation data. Kuhn et al. [28] 
also demonstrated the association between serum concentrations of individual bile 
acids and colon cancer risk and was the first to show the importance of conjugated 
bile acids compared to that of unconjugated bile acids. They observed statisti-
cally significant positive associations between most conjugated primary bile acids 
(glyco-CA, tauro-CA, glyco-tauro-CDCA, tauro-CDCA, and glyco-hyocholic acid 
[GHCA]) and colon cancer risk.
The clinical usefulness of serum bile-acid profiles has also been analyzed in 
several diseases other than colorectal cancer. Recent reports have demonstrated that 
the concentration of conjugated secondary bile acids (glycol-DCA, glycol-LCA, 
tauro-DCA, and tauro-LCA), but not of the unconjugated forms, increases paral-
lelly with the progression of the disease, especially in patients with Alzheimer’s 
disease and dementia. Nho et al. [26] were the first to show that altered bile-acid 
profiles and increased ratios of glyco-DCA:CA, tauro-DCA:CA, and glyco-
LCA:CDCA were significantly associated with structural and functional changes 
in the brain, as indicated by greater atrophy and reduced glucose metabolism. 
Higher levels of secondary conjugated bile acids (glyco-DCA, glycol-LCA, and 
tauro-LCA) were significantly associated with worse cognitive function in 1,464 
subjects, including 370 cognitively normal older adults, 284 individuals with early 
mild cognitive impairment (MCI), 505 individuals with late MCI, and 305 patients 
with Alzheimer’s disease [25]. The increase in the concentration of conjugated bile 
acids in the blood should be considered to be caused by the high-fat diet-stimulated 
5
Role of Gut Microbiota in Bile-Acid Metabolism
DOI: http://dx.doi.org/10.5772/intechopen.100440
increase in the bile-acid biosynthetic reactions in the liver and the decrease in the 
bile-acid deconjugation reactions in the intestinal tract, indicating a decrease in 
the gut microbiota carrying the deconjugation gene for BSH, as has been men-
tioned above.
We previously performed a correlation analysis between the bile-acid profile 
and gut microbiota in a fatty liver model and a colon cancer model in mice fed a 
high-fat diet and indicated that this correlation analysis is useful for assessing the 
functionality of dietary factors [29, 30]. High-fat dietary load increased serum lev-
els of conjugated bile acids (tauro-CA, tauro-DCA) and decreased levels of uncon-
jugated bile acids (such as CA), but the administration of epigallocatechin gallate 
(EGCG), a functional ingredient in tea, normalized bile-acid profiles. Furthermore, 
an analysis of gut microbiota revealed a positive correlation between an increase in 
the abundance of Akkermansia and their effects on bile acids [29]. Similarly, in the 
colon cancer model, we found that agarooligosaccharide suppressed the increase 
in levels of taurine-conjugated bile acids and suppressed the increase of bacteria 
classified into Clostridium subcluster XIVa that are involved in secondary bile-acid 
metabolism.
As described above, quantitative bile-acid profile measurement using the LC–
MS/MS method has made it possible to obtain integrated bile-acid information that 
distinguishes between conjugated and unconjugated types; consequently, the roles 
of bile acids in physiology and pathophysiology are being elucidated. It is important 
to note that such analysis should be conducted with the understanding that the 
bile-acid profiles are influenced by dietary factors, including high-fat diet, liver 
function, lipid metabolism, cholesterol level, and gut microbiota.
4. An inhibitor of ileal bile-acid transporter (IBAT)
In a gnotobiotic experiment wherein feces of patients with chronic constipation, 
especially those with delayed intestinal transit time, were transplanted into germ-free 
mice, short chain fatty acids and secondary bile acids, which are metabolites of the 
gut microbiota, were identified to be factors that promote intestinal peristalsis, and 
the administration of butyric acid or DCA activated serotonin signals in the gut and 
restored the decreased intestinal peristalsis of these gnotobiotic mice [31]. In addition, 
the amount of bile acids in the feces of patients with chronic constipation and irritable 
bowel syndrome was found to be decreased, suggesting that improving this decrease in 
the bile-acid concentration in the large intestine may be a suitable therapeutic strategy.
Elobixibat, the first inhibitor of IBAT, expressed in epithelial cells in the termi-
nal ileum and suppresses the reabsorption of bile acids, thereby causing bile acids 
to flow into the lumen of the large intestine (Figure 2). Elobixibat is effective as a 
therapeutic agent for chronic constipation as it induces a secondary bile-acid signal, 
causing water to be secreted into the lumen of the large intestine and thus promot-
ing gastrointestinal peristalsis [3, 4]. These physiological effects of bile acids are 
thought to be mediated by the TGR5 receptor localized in intestinal cells. The analy-
sis of bile acids in feces has indicated an increase in DCA levels after the admin-
istration of Elobixibat compared to those before administration [23]. Intestinal 
neuroendocrine cells (EC cells) are considered to be the main TGR5 receptor-
expressing cells, and TGR5 receptor-deficient mice have been demonstrated to have 
decreased intestinal peristalsis [32]. The binding of bile acids to the TGR5 receptor 
expressed on the luminal side of EC cells is hypothesized to activate serotonin 
synthesis signals and enhance secretion, leading to the activation of peristalsis. The 
reactivity of the TGR5 receptor to different bile acids varies; the TGR5 receptor has 
high reactivity with LCA and DCA and low reactivity with CDCA and CA [33]. 
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TGR5 receptor expression is also reported to be affected by gut microbiota [12]. 
In other words, the dose dependence of the efficacy of Elobixibat may be strongly 
influenced by the intestinal bile-acid profile and intestinal flora of each individual. 
In addition, Elobixibat activates bile-acid metabolism, and in future studies, it is 
necessary to consider the effects of Elobixibat on the whole body, including effects 
on cholesterol metabolism and fatty liver.
An observational study that used the Japanese version of the Patient 
Assessment of.
Constipation-Quality of Life (PAC-QOL) questionnaire has demonstrated 
that the scores of physical discomfort and psychosocial discomfort significantly 
decreased in patients with constipation after the treatment with Elobixibat for 
4 weeks, indicating the possibility that Elobixibat could affect the gut-brain axis [34].
5. Akkermansia muciniphila and bile-acid signals for well-being
Well-being is a key word in the WHO’s definition of health: a state of complete 
physical, mental, and social well-being and not merely the absence of disease or 
infirmity. Thus, medical care aimed at wellbeing is necessary. Recent reports have 
revealed the involvement of gut microbiota and bile-acid metabolism in extending 
healthspan and lifespan [35]. The gut microbiota of two different mouse models 
of progeria was characterized by intestinal dysbiosis with alterations including 
an increase in the abundance of Proteobacteria and Cyanobacteria and a decrease 
in the abundance of Verrucomicrobia compared to the gut microbiota of control 
mice. Fecal microbiota transplantation from wild-type mice enhanced healths-
pan and lifespan in both progeroid mouse models, and transplantation with the 
Verrucomicrobia Akkermansia muciniphila was sufficient to exert beneficial effects. 
Furthermore, an analysis of gut microbiota metabolites revealed that various 
bile acids were reduced in the progeroid mouse models, and this dysregulation in 
bile acids was improved by transplantation with Akkermansia muciniphila [35]. 
Figure 2. 
Ileal bile-acid transporter (IBAT) inhibitor (elobixibat) and its effect on the function of the large intestine. 
Elobixibat inhibits IBAT expressed in epithelial cells in the terminal ileum and partially suppresses bile-acid 
reabsorption. The flow of bile acids into the lumen of the large intestine activates TGR5 receptors, causing the 
secretion of water into the lumen of the large intestine and thus promoting gastrointestinal peristalsis.
7
Role of Gut Microbiota in Bile-Acid Metabolism
DOI: http://dx.doi.org/10.5772/intechopen.100440
Morita et al. [36] reported that Akkermansia was more abundant in  individuals 
from Ogimi and Lachnospiraceae, Collinsella, Peptococcus, and S24–7 were more 
abundant in individuals not from Ogimi. Ogimi is a village located in the northern 
region of Okinawa’s main island and has a population of approximately 3,000; it 
is known as the village of longevity in Japan. Grajeda-Iglesias et al. [37] recently 
demonstrated that Akkermansia muciniphila, especially if it is pasteurized, causes 
major changes in metabolism, elevating the concentrations of several metabolites 
that have been previously associated with positive effects on health in mouse mod-
els. Pasteurized Akkermansia muciniphila was more efficient than live Akkermansia 
muciniphila in elevating the intestinal and circulatory concentrations of poly-
amines, short-chain fatty acids, 2-hydroxybutyrate, and multiple bile acids, all of 
which may have a positive impact on human health.
Bile-acid analysis by LC–MS/MS has enabled the identification of new metabo-
lites related to health and longevity. Detailed metagenomic analysis and intestinal 
metabolite analysis of Japanese centenarians recently revealed a novel bile-acid 
metabolite, isoallo-lithocholic acid, which has a bactericidal effect on specific 
intestinal bacteria [38]. Although details of the effect of Akkermansia muciniphila on 
bile-acid metabolism are not fully understood, our previous analysis using a high-fat 
diet load mouse model suggests that the bacterium promotes the deconjugation of 
conjugated bile acids and suppresses the production of secondary bile acids [29]. A 
double-blind comparative study in obese individuals has already been conducted to 
investigate whether Akkermansia muciniphila improves the intestinal environment 
[39]. They demonstrated that Akkermansia muciniphila reduced the levels of the 
relevant blood markers for liver dysfunction and inflammation while the overall gut 
microbiome structure was unaffected after three months of supplementation [39].
The neuroprotective effect of tauroursodeoxycholic acid (TUDCA), a hydro-
philic bile acid and naturally produced in the liver by conjugation of taurine to 
UDCA, has been recently elucidated [40]. Several studies have shown that TUDCA 
has neuroprotective action in several models of neurodegenerative disorders, 
including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease [40]. 
Currently, there is one registered clinical trial with TUDCA in Alzheimer’s disease, 
in the United States (Clinical Trials registration: NCT03533257).
Additionally, countermeasures against sarcopenia are important clinical issues 
in research aimed at improving well-being. Maintaining muscle strength with diet 
and exercise is important to prevent sarcopenia, and recent studies have shown that 
TGR5 present in the skeletal muscle plays an important role in muscle maintenance 
[41, 42]. Exercise-induced stimulation enhances TGR5 receptor expression in the 
skeletal muscle, and the increased after-meal levels of bile acids in the blood act as 
ligands for the TGR5 receptor, helping maintain muscle and prevent sarcopenia. 
Furthermore, TGR5 signaling in the muscle activates muscle metabolism and 
enhances glucose clearance, which also has a positive effect on glucose metabolism 
[41, 42]. Countermeasures against so-called frail complexes, such as sarcopenia, 
locomotive syndrome, and frailty, are extremely important clinical issues in sup-
porting medical care aimed at improving well-being. It should be emphasized that 
the gut microbiota-bile acid-receptor signal is a novel therapeutic and prophylactic 
target molecule for improving frailty.
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